The Present Clinical Treatment and Future Emerging Interdisciplinary for Heart Failure: Where we are and What we can do

被引:0
作者
Yu Yang
Jiamin Gao
Zhen Qin
Yongzheng Lu
Yanyan Xu
Jiacheng Guo
Xiaolin Cui
Jinying Zhang
Junnan Tang
机构
[1] The First Affiliated Hospital of Zhengzhou University,Department of Cardiology
[2] Henan Province Key Laboratory of Cardiac Injury and Repair,School of Medicine
[3] Henan Province Clinical Research Center for Cardiovascular Diseases,undefined
[4] The Chinese University of Hong Kong,undefined
来源
Intensive Care Research | 2023年 / 3卷 / 1期
关键词
Heart failure; Clinical Treatment; Interdisciplinary; Future Perspective;
D O I
10.1007/s44231-023-00029-4
中图分类号
学科分类号
摘要
Heart failure is a complex clinical syndrome caused by the progression to severe stages of various cardiac diseases, characterized by high morbidity and mortality. With the increasing aging of the population and the poor control of high-risk factors for heart failure such as hypertension and diabetes, the incidence of heart failure remains high. Therefore, there is widespread global attention regarding the various treatments for heart failure. Currently, pharmacological therapy, associated device therapy, interventional therapy, and end-stage surgical related therapy are the main clinical treatments for heart failure. Heart failure treatment is gradually evolving to be more precise, safe, and effective, as traditional therapies can no longer match clinical needs. A number of cutting-edge research studies are being conducted on the treatment of heart failure, based on the different pathogenesis and causes of heart failure, to treat patients with heart failure in a multifaceted and integrated way. This article summarizes the current clinical treatment of heart failure and the latest therapeutic advances in heart failure in current research to further promote the standardized management and treatment of heart failure and improve patient prognosis.
引用
收藏
页码:3 / 11
页数:8
相关论文
共 92 条
  • [21] Chen CA(2011)The role of beta-blockers in the treatment of chronic heart failure Trends Pharmacol Sci 32 206-1195
  • [22] McDonagh TA(2017)Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives Eur Heart J Cardiovasc Pharma. 3 48-3644
  • [23] Mollace V(2020)Diuretic therapy for patients with heart failure: jacc state-of-the-art review J Am Coll Cardiol 75 1178-434
  • [24] McMurray JJV(2019)Treatments targeting inotropy Eur Heart J 40 3626-1784
  • [25] Kubon C(2020)Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 Inhibitors: JACC state-of-the-art review J Am Coll Cardiol 75 422-1893
  • [26] Pitt B(2017)The clinical use of ivabradine J Am Coll Cardiol 70 1777-456
  • [27] Pedro Ferreira J(2020)Vericiguat in patients with heart failure and reduced ejection fraction N Engl J Med 382 1883-828
  • [28] Zannad F(2019)Heart failure and atrial fibrillation, like fire and fury JACC Heart Fail 7 447-2508
  • [29] Felker GM(2016)Rate control in atrial fibrillation Lancet 388 818-930
  • [30] Maack C(2020)Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: The RATE-AF randomized clinical trial JAMA 324 2497-1764